Maloney Elected President of AAOS; Shadan Appointed to AdvaMed Board; Enhanced MRI Detects Early Osteoarthritis!
Elizabeth Hofheinz, M.P.H., M.Ed. • Wed, April 12th, 2017
William J. Maloney III, M.D., Elected President of AAOS
William J. Maloney III, M.D., the Elsbach-Richards Professor of Surgery, and professor and chairman of the Department of Orthopaedic Surgery at Stanford University School of Medicine, has been elected as the president of the American Academy of Orthopaedic Surgeons (AAOS) Board of Directors. Dr. Maloney will serve as president of the organization in 2017-2018.
Dr. Maloney has given his time to many AAOS committees, including the Council on Education. He currently serves as co-chair of the AAOS/American Board of Orthopaedic Surgery (ABOS) Combined Task Force on Maintenance of Certification (MOC). Previously, he was chair of the American Joint Replacement Registry Board of Directors (AJRR), and on the boards of directors for the Knee Society, the Hip Society, the Western Orthopaedic Association, and the American Association of Hip and Knee Surgeons (AAHKS). Dr. Maloney is a past president of the Hip Society.
Dr. Maloney attended undergraduate school at Stanford University and received a medical degree from Columbia College of Physicians and Surgeons in New York City. He interned and then served as junior, senior and chief resident in orthopedic surgery at Stanford Medical Center, and also was a clinical fellow in hip reconstruction surgery at Massachusetts General Hospital in Boston. Prior to becoming orthopedic chair at Stanford, Dr. Maloney served on the faculty of the Department of Orthopaedic Surgery at Washington University School of Medicine and as chief of orthopaedics at Barnes-Jewish Hospital in St. Louis, Missouri.
Asked about his undergraduate degree, Dr. Maloney commented to OTW, “My background in psychology was pretty distant. I graduated from Stanford with a degree in psychology in 1979. In broad strokes, studying psychology provided a framework to try and understand how one's background and experiences impact one's point of view on a particular topic as well as the unrecognized or unspoken biases that may exist—sometimes helps in developing consensus and getting people to move forward.”
“It is an exciting and challenging year for our organization. I hope to help our new CEO, Tom Arend on board and ease that transition. My priority in general is to enhance the value of membership and respond to the needs of our members.”
“I have four high priority initiatives:
- Evaluate an alternative pathway for MOC that does not involve a high stakes exam.
- Optimize our advocacy efforts on both the federal and state level.
- Determine what our members will need in terms of outcome data collection and performance measure reporting and evaluate the roll of an AAOS registry either in house or in conjunction with a third party in fulfilling those needs.
- Accelerate our learning management platform rollout to bring our wide variety of educational resources to our members in a more efficient way.”
Martha Shadan Appointed to AdvaMed Board
Martha Shadan, president and chief executive officer of Minnesota-based Rotation Medical Inc., has been appointed to the board of directors of the Advanced Medical Technology Association (AdvaMed). According the organization’s website, “AdvaMed is a trade association that leads the effort to advance medical technology in order to achieve healthier lives and healthier economies around the world. It represents 80 percent of medical technology firms in the U.S. and acts as the common voice for companies producing medical devices, diagnostic products and health information systems.”
Since 2015, Shadan has served on the board of directors for AdvaMed’s Accel division, which is focused on smaller medical technology manufacturers. She is also a member of the leadership circle for AdvaMed’s Women’s Executive Network (WEN), an initiative promoting and cultivating female executive leadership across the medical technology industry, and co-chairs the organization’s Physician Owned Companies Working Group.
“AdvaMed is pleased to have someone of Martha’s caliber on our Board of Directors,” said Scott Whitaker, president and CEO of AdvaMed, in the April 4, 2017 news release. “Martha has three decades of industry experience, including senior leadership positions at Zimmer and Covidien prior to her nearly four years at the helm of Rotation Medical. The depth and breadth of knowledge that she brings to AdvaMed will help ensure that the entire ecosystem of medical technology is healthy and strong so we can continue our work to enhance the lives of patients worldwide. In addition, as a representative of our Accel Board, Martha will be a strong advocate for the unique needs of the association’s emerging members.”
“Shadan joined Rotation Medical in 2013, bringing more than 30 years of marketing and commercialization expertise to her role as CEO,” says the news release. “Under her leadership, the company’s sales for 2016 exceeded expectations by 30 percent, and it secured $12 million in series B financing to continue U.S. commercialization activities for the Rotation Medical Bioinductive Implant for rotator cuff tears. Cleared by the U.S. Food and Drug Administration in March 2014, the Bioinductive Implant helps tendons heal through the induction of new tissue growth. The collagen-based implant is about the size of a postage stamp and it is part of the Rotation Medical rotator cuff system, which also includes disposable instruments that allow the arthroscopic procedure to be performed easily and quickly.”
Shadan commented to OTW, “The medical industry is adapting to a changing ecosystem, and one of the things that I’ve learned at Rotation Medical is that continuing to innovate to address clinical needs as well as opportunities remains a key driver, and that innovation has to be rooted in value-based approaches. I believe that helping medical device companies explore how they can view new approaches through a value lens is exciting. In my new role on the board with AdvaMed, I know we can help propel progressive approaches and disruptive technology for today and tomorrow.”
Enhanced MRI Detects Early Osteoarthritis!
New research performed at University of California, San Francisco, Hospital for Special Surgery (HSS) in New York, and Mayo Clinic in Rochester, Minnesota is advancing our ability to detect early changes in articular cartilage after an injury and therefore early onset of osteoarthritis.
The study, “Effects of Surgical Factors on Cartilage Can Be Detected Using Quantitative Magnetic Resonance Imaging after Anterior Cruciate Ligament Reconstruction,” was published in the April 1, 2017 edition of The American Journal of Sports Medicine.
Researchers, who studied 54 patients who underwent ACL reconstruction, utilized quantitative magnetic resonance (qMR) at baseline and six months postop. They wrote, “We hypothesized that specific patient and surgical factors affecting cartilage matrix composition after anterior cruciate ligament (ACL) reconstruction (ACLR) can be detected using T1ρ and T2 relaxation times. Prolonged relaxation times in multiple regions demonstrate how the injury affects the entire joint after an ACL tear.”
Scott Rodeo, M.D., a sports medicine surgeon at HSS and co-author on the study, told OTW, “The underlying issue in this study relates to the well-established risk of post-traumatic osteoarthritis in the ACL injured knee. However, the clinical challenge is that we need better methods for early detection of adverse cartilage changes in the injured knee. Plain radiographs, and even standard morphological MRI, are relatively insensitive for detection of early changes in the ACL injured knee. Our goal was to use more sensitive, quantitative MRI techniques to detect early changes in the structure and composition of articular cartilage. An important goal was to evaluate the ability to carry out reproducible quantitative MR imaging at different institutions in the U.S. The validation of sensitive techniques to detect early changes in structure and composition of cartilage will allow for a rigorous evaluation of novel therapeutic agents that may be used in these patients to prevent or forestall progressive degenerative changes.”
“We found that the injured knee had significantly prolonged T1rho and T2 relaxation times in the tibiofemoral compartment at baseline and six months, verifying the ability to detect changes in cartilage matrix composition in ACL injured patients. We also found that higher T1rho and T2 in the medial tibial plateau and lateral tibial plateau cartilage were correlated with lower outcome scores (more pain and symptoms). A further important finding is that lateral meniscal tears treated with repair had significantly shorter T1rho relaxation times than those treated with excision, suggesting that the decreased cartilage coverage after meniscus excision could affect the overlying femoral cartilage.”
“A notable finding was the prolonged T1rho and T2 times at six months in the uninjured knees, which may be caused by increased loading during rehabilitation, especially in the patellofemoral articular cartilage.”
“I believe that an important message is that quantitative MRI techniques can be used to obtain information about changes in the microstructure and biomechanical composition of articular cartilage early after ACL injury, long before changes are noted on radiographs and even standard morphological MRI. The further validation and standardization of such quantitative MRI techniques may allow for a sensitive tool to evaluate the potential ‘chondroprotective’ effects of novel therapeutic agents that may be used in patients to prevent progressive articular cartilage degenerative changes.”